In this issue:
Tafasitamab + lenalidomide vs. rituximab-based regimens in relapsed/ refractory DLBCL
MRD-guided stop and start of venetoclax + ibrutinib in relapsed/refractory CLL
Blinatumomab then POMP maintenance in older Ph-negative B-cell ALL
First-line venetoclax, daunorubicin and cytarabine for AML
Cost effectiveness of shortening treatment based on interim PET in DLBCL
Follow-up of first-line ibrutinib for CLL/SLL with high-risk genomic features
Follow-up of relapsed/ refractory FLT3-positive AML treated with gilteritinib
Fixed-duration ibrutinib + venetoclax as first-line treatment of CLL
Brentuximab vedotin consolidation after autologous SCT for Hodgkin lymphoma
Please login below to download this issue (PDF)